Tesamorelin for Men: Visceral Fat, TRT, Glucose and What to Rule Out First

The first phase 3 trial, in the New England Journal of Medicine in 2007, randomized 412 people with HIV and abdominal fat accumulation, 86 percent men, to tesamorelin 2 mg daily or placebo for 26 weeks. Visceral fat on CT fell 15.2 percent on treatment and rose 5.0 percent on placebo, triglycerides fell, IGF-1 rose 81 percent, and glycemic measures did not differ. A pooled analysis of that trial and a second of the same design, in the Journal of Clinical Endocrinology and Metabolism in 2010, covered 806 patients and reported a treatment effect of about 15% at week 26, maintained to 52 weeks in those who continued and returning toward baseline in those switched to placebo. Every trial that measured it found no significant change in the fat under the skin.

For men. These trials describe men more than women simply because of who enrolled. They still describe a specific population, HIV-associated fat redistribution, at 2 mg daily, which is four times Pepti's typical compounded direction. They measured the deeper fat on imaging, not appearance, weight or a six-pack.

A 2012 trial in the Journal of Clinical Endocrinology and Metabolism gave 60 abdominally obese adults with reduced growth hormone secretion tesamorelin 2 mg or placebo for 12 months. It reported a selective reduction in visceral fat with no effect on subcutaneous fat, improved triglycerides and C-reactive protein, and no worsening of glucose. It is the most direct evidence that the visceral-fat finding belongs to the drug rather than to HIV. It is also one trial, in people selected for low growth hormone secretion, and a man with a normal pituitary is not quite that population.

A 2014 JAMA trial (50 people) and a 2019 Lancet HIV trial (61 people) in people with HIV reported less liver fat. A 2012 Archives of Neurology trial randomized 152 adults aged 55 to 87 to tesamorelin 1 mg or placebo at bedtime for 20 weeks and reported a favorable effect on a cognitive composite, alongside a 117 percent rise in IGF-1 and a 7.4 percent fall in body fat. None is an approved use.

Growth hormone is released in bursts, the largest during deep sleep. In healthy men sampled around the clock, daily secretion fell by roughly 14 percent per decade, and at any given age each extra unit of body mass index cut it by a further 6 percent or so (Journal of Clinical Endocrinology and Metabolism, 1991). The man who has gained weight since his thirties has lost growth hormone signaling on two counts, and visceral fat is the most growth-hormone-responsive fat in the body. That is the logic for a GHRH analogue in men. It is logic, not a trial in healthy men.

The clearest sex-specific result for a GHRH analogue comes from a related molecule, not tesamorelin. In a 1997 trial in the Journal of Clinical Endocrinology and Metabolism, ten women and nine men aged 55 to 71 self-injected a GHRH(1-29) analogue nightly for 16 weeks. Growth hormone and IGF-1 rose in both sexes, but the increases in lean mass and insulin sensitivity were seen in men only. It is nineteen people, a different molecule, and the investigators said more work was needed.

Tesamorelin acts on the growth hormone axis. It is not described as moving testosterone, and growth-hormone-axis peptides do not raise it. If two morning draws confirm low testosterone alongside symptoms, that is hypogonadism, treated with testosterone under its own monitoring, not with a GHRH analogue. Peptides for testosterone covers what has and has not been studied.

The approved label says plainly that tesamorelin is not indicated for weight-loss management because its effect on weight is neutral. A man expecting the scale to move has picked the wrong tool; where weight itself is the problem, the GLP-1 medications have the trial evidence. A tape measure at the navel, taken the same way each month, matches what the trials measured better than a scale does. The comparison is in tesamorelin vs semaglutide.

Tesamorelin is prescribed alongside TRT where visceral fat is the specific goal. The two treatments move overlapping markers, so every prescriber involved should know about the other. IGF-1 is what the growth hormone side is tracked on, and testosterone can raise IGF-1 too, so an IGF-1 that has moved in a man taking both is not automatically the peptide's doing. Glucose is the marker the two pull on in opposite directions: growth hormone reduces insulin sensitivity, while androgens may lower blood glucose in diabetic patients. There is no randomized trial of tesamorelin given alongside testosterone replacement, and no established interaction list. The trials of recombinant growth hormone plus testosterone in older men used the hormone itself, not a GHRH analogue, and cannot be read as evidence for tesamorelin. More in can you take peptides with testosterone.

The approved label records HbA1c of 6.5% or higher in 5% of treated patients against 1% on placebo over 26 weeks, and directs that glucose status be evaluated before starting and during treatment. A prediabetic HbA1c does not exclude tesamorelin, but it is a different prescribing decision. Diabetes, prediabetes or a borderline fasting glucose belongs on the intake.

Tesamorelin raises growth hormone and IGF-1. The approved label contraindicates it in active malignancy, requires any prior malignancy to be inactive with treatment complete, and states that the effects of prolonged IGF-1 elevation are unknown. Growth-hormone-axis peptides are not described as moving PSA, but a 2004 meta-regression in The Lancet reported associations between circulating IGF-1 and the risk of certain common cancers in observational cohorts. That is an association, not a demonstrated effect of treatment, and it is why a personal or family history of prostate or any other cancer goes on the intake in full.

The approved product is contraindicated where the hypothalamic-pituitary axis is disrupted, including pituitary surgery, head irradiation or head trauma. Sleep apnoea is worth flagging separately: it lowers growth hormone and testosterone, and the fluid retention on the growth hormone side can complicate it.

No study in the live research has looked at tesamorelin and male fertility. If conception is a goal, raise it with your physician before starting. See do peptides affect fertility.

The 2026 WADA Prohibited List names tesamorelin as a prohibited GHRH analogue, prohibited at all times. If you are tested by any body, tell your physician before starting.